Multidisciplinary and Comprehensive Chinese Medicine for Advanced Non-Small Cell Lung Cancer Patients: A Retrospective S
- PDF / 282,274 Bytes
- 6 Pages / 612.284 x 824.882 pts Page_size
- 40 Downloads / 196 Views
C
hinese Journal of Integrative Medicine
•1•
Available online at link.springer.com/journal/11655 Journal homepage: www.cjim.cn/zxyjhen/zxyjhen/ch/index.aspx E-mail: [email protected]
Original Article
Multidisciplinary and Comprehensive Chinese Medicine for Advanced Non-Small Cell Lung Cancer Patients: A Retrospective Study of 855 Cases HUANG Xian-ge, ZHU Li-hua, ZHOU Lei, XU Wei-jie, YAO Yi-lin, ZHOU Zhi-yi, and LI He-gen Objective:: To investigate the effects of multidisciplinary and comprehensive Chinese medicine (CM) ABSTRACT Objective treatments on progression-free survival (PFS) and median survival time (MST) in patients with advanced nonMethods:: Clinical small cell lung cancer (NSCLC) and identify factors that influence progression and prognosis. Methods data of 855 patients with advanced NSCLC who received multidisciplinary and comprehensive CM treatments at Longhua Hospital from January 2009 to December 2018 were retrospectively analyzed. Univariate analysis was performed by the Kaplan-Meier method and log-rank sequential inspection. Multivariate analysis of significant variables from the univariate analysis was performed with Cox regression modeling. Key factors correlated to progression and prognosis were screened out, and a Cox proportional hazard model was established to calculate Results:: The PFS and MST of 855 advanced NSCLC patients were 9.0 and 26.0 months, the prognostic index. Results respectively. The 1-, 2-, 3-, and 5-year survival rates were 79.2%, 54%, 36.2%, and 17.1%, respectively. Gender, pathologic type, and clinical stage were independent prognostic risk factors; surgical history, radiotherapy, treatment course of Chinese patent medicine, intravenous drip of Chinese herbal preparation, duration of oral administration of Chinese herbal decoction (CHD), and intervention measures were independent prognostic protective factors. Gender was an independent risk factor for progression, while operation history and oral CHD administration duration were independent protective factors (all P 48 months
0.182
442.022
0.022
0.000
Intervention measures
15.715
0.001
CM + CHEMO
0.155
13.242
0.569
0.000
CM + TG
0.216
11.128
0.487
0.001
CM + CHEMO + TG
0.173
12.956
0.536
0.000
Progression measures
0.085
34.317
0.607
0.000
Notes: NSCLC, non-small cell lung cancer; CM, Chinese medicine; ET, external treatment; CPM, Chinese patent medicine; CHP-IV, Chinese herbal preparation intravenous administration; CHEMO, chemotherapy; TG, target therapy
The survival curves of advanced NSCLC patients after receiving different comprehensive CM treatments are shown in Figure 1. The overall survival of advanced NSCLC patients was effectively prolonged when they received regular and continuous comprehensive CM treatments.
Forest Plot of Prognostic Factors in Advanced NSCLC Patient According to the data obtained from the Cox
0.
Duration for CHD
Figure 2.
0. 50 0. 75 1. 00 1. 25 1. 50
3.679
0
0.111
25
5–8 courses
Forest Plot of Prognostic Factors for Advanced NSCLC Patients
Analysis o
Data Loading...
